BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23790165)

  • 1. Expression of Ki-67 and p53 in meningiomas.
    Pavelin S; Becic K; Forempoher G; Mrklic I; Pogorelic Z; Titlic M; Andelinovic S
    Neoplasma; 2013; 60(5):480-5. PubMed ID: 23790165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
    Ozen O; Demirhan B; Altinörs N
    Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas.
    Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K; Nishisaka T; Fukuhara T; Inai K
    Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
    Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
    APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of morphologically benign biologically aggressive meningiomas.
    Rao S; Sadiya N; Doraiswami S; Prathiba D
    Neurol India; 2009; 57(6):744-8. PubMed ID: 20139503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
    Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
    Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of p63 immunoreactivity with tumor grade in meningiomas.
    Rushing EJ; Olsen C; Man YG
    Int J Surg Pathol; 2008 Jan; 16(1):38-42. PubMed ID: 18203782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays.
    Terzi A; Saglam EA; Barak A; Soylemezoglu F
    Pathol Res Pract; 2008; 204(5):305-14. PubMed ID: 18374497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
    Roser F; Samii M; Ostertag H; Bellinzona M
    Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.
    Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S
    Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Proliferative markers of meningiomas: immunohistochemical analysis and prognostic value].
    Korshunov AG; Shishkina LV; Golanov AV
    Arkh Patol; 2002; 64(1):29-33. PubMed ID: 11889696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of p53, MDM2 protein and Ki-67 antigen in recurrent meningiomas.
    Ohkoudo M; Sawa H; Hara M; Saruta K; Aiso T; Ohki R; Yamamoto H; Maemura E; Shiina Y; Fujii M; Saito I
    J Neurooncol; 1998 May; 38(1):41-9. PubMed ID: 9540056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study].
    Wang CL; Mei JH; Wang SS; Xu S; Xu LL; Xiong YF
    Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):156-60. PubMed ID: 20450760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression of survivin and Ki-67 in meningiomas: correlation with grade and clinical outcome.
    Kayaselçuk F; Zorludemir S; Bal N; Erdogan B; Erdogan S; Erman T
    J Neurooncol; 2004; 67(1-2):209-14. PubMed ID: 15072469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferation and progesterone receptor status in benign meningiomas are not age dependent.
    Roser F; Nakamura M; Ritz R; Bellinzona M; Dietz K; Samii M; Tatagiba MS
    Cancer; 2005 Aug; 104(3):598-601. PubMed ID: 15952201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study.
    Pistolesi S; Boldrini L; Gisfredi S; De Ieso K; Camacci T; Caniglia M; Lupi G; Leocata P; Basolo F; Pingitore R; Parenti G; Fontanini G
    Neuropathol Appl Neurobiol; 2004 Apr; 30(2):118-25. PubMed ID: 15043709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [P53 protein expression and proliferative potential in non-recurrent and recurrent meningiomas].
    Miyagami M; Kanou T; Nakamura S
    No To Shinkei; 1996 Aug; 48(8):719-25. PubMed ID: 8797205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 Protein expression in meningiomas - a clinicopathologic study of 55 patients.
    Aguiar PH; Agner C; Simm R; Freitas AB; Tsanaclis AM; Plese P
    Neurosurg Rev; 2002 Aug; 25(4):252-7. PubMed ID: 12172734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of E-cadherin and catenins in meningioma: ubiquitous expression and its irrelevance to malignancy.
    Shimada S; Ishizawa K; Hirose T
    Pathol Int; 2005 Jan; 55(1):1-7. PubMed ID: 15660696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.